Is Sage Therapeutics a Contrarian Buy?
Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders. The stock plummeted by more than 53% after the company revealed that its blockbuster drug candidate, zuranolone, failed to win approval from the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD).
Zuranolone, which Sage Therapeutics developed in collaboration with (NASDAQ: BIIB), is a novel antidepressant designed to offer fast and durable relief from depressive symptoms, with a short course of treatment and minimal side effects.
Image Source: Getty Images.
Source Fool.com
Biogen Inc. Stock
€188.45
-3.150%
With 53 Buy predictions and 2 Sell predictions Biogen Inc. is one of the favorites of our community.
As a result the target price of 289 € shows a very positive potential of 53.36% compared to the current price of 188.45 € for Biogen Inc..
